Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4373296 | 0.96 | HRH3 (0.46) | HRH3CXCR4CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL4385965 | 0.94 | HRH3 (0.50) | HRH3CYP1A2MAPK1SMN1; SMN2HRH4 | |
| SCHEMBL4378949 | 0.91 | CHRM5 (0.34) | HRH3CYP1A2MAPK1SMN1; SMN2CCR3 | |
| SCHEMBL4383518 | 0.86 | CHRM5 (0.39) | HRH3CYP1A2MAPK1SMN1; SMN2CCR3 | |
| SCHEMBL4378807 | 0.84 | CHRM5 (0.43) | HRH3CYP1A2MAPK1SMN1; SMN2ACHE | |
| SCHEMBL4667708 | 0.83 | GNAO1 (0.40) | HRH3CXCR4CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL4379892 | 0.82 | KEAP1 (0.48) | CYP1A2SMN1; SMN2SIGMAR1 | |
| SCHEMBL4375229 | 0.82 | KDM1A (0.38) | SLC6A2SLC6A4CCR3SIGMAR1GNAO1 | |
| SCHEMBL4664113 | 0.79 | HRH3 (0.43) | HRH3CYP1A2MAPK1SMN1; SMN2GNAO1 | |
| SCHEMBL28206582 | 0.79 | GNAO1 (0.56) | GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262201-B1 | For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals | ASTRAZENECA AB (SE) | 2007-08-28 | — | — | US | claimed |
| EP-1119567-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-04 | — | — | EP | claimed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | HENNEQUIN LAURENT FRANCOIS ANDRE | 2008-12-18 | — | — | US | disclosed |
| US-7371765-B2 | Quinoline derivatives having VEGF inhibiting activity | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| US-7262201-B1 | For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals | ASTRAZENECA AB (SE) | 2007-08-28 | — | — | US | disclosed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20060148819-A1 | Chemical compounds | HENNEQUIN LAURENT F A | 2006-07-06 | — | — | US | disclosed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| US-20030207878-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | US | disclosed |
| EP-1313726-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| EP-1309587-A1 | CINNOLINE COMPOUNDS | AstraZeneca AB (SE) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002016348-A1 | ANTIANGIOGENIC BICYCLIC DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012228-A1 | CINNOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| EP-1119567-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021955-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | VEGFA, FLT1, FLT4 | HRH3 27/4885CXCR4 114/4885CYP1A2 1059/4885 |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | HRH3 739/4885CXCR4 166/4885CYP1A2 807/4885 |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | VEGFA, FLT1, FLT4 | HRH3 145/4885CXCR4 149/4885CYP1A2 1687/4885 |
| US-20060148819-A1 | Chemical compounds | VEGFA, NOS3, FLT4 | HRH3 5/4885CXCR4 13/4885CYP1A2 249/4885 |
| US-20030207878-A1 | Chemical compounds | CYP3A7, HTR3C, CNR1 | HRH3 44/4885CXCR4 110/4885CYP1A2 65/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | HRH3 204/4885CXCR4 9/4885CYP1A2 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.